Yahoo
NasdaqCM - Delayed Quote USD

MindWalk Holdings Corp. (HYFT)

1.0300 -0.0500 (-4.63%)
At close: November 10 at 4:00:01 PM EST
Chart Range Bar
Loading chart for HYFT
  • Previous Close 1.0800
  • Open 1.0600
  • Bid 1.5200 x 100
  • Ask 1.7400 x 200
  • Day's Range 0.9687 - 1.0685
  • 52 Week Range 0.9687 - 2.9900
  • Volume 143,810
  • Avg. Volume 237,270
  • Market Cap (intraday) 49.002M
  • Beta (5Y Monthly) 0.78
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2600
  • Earnings Date (est.) Dec 15, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 4.33
  • Motley Fool Rating Bearish

MindWalk Holdings Corp. operates as a bio-native AI company. The company discovers and develops biologics through HYFT Technology and LensAI platform, as well as develops AI drug discovery and biologics through ReefIQ technology. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company is headquartered in Austin, Texas.

www.mindwalkai.com

74

Full Time Employees

April 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/10/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

HYFT
43.41%
S&P 500 (^GSPC)
9.87%

1-Year Return

HYFT
41.81%
S&P 500 (^GSPC)
10.08%

3-Year Return

HYFT
33.97%
S&P 500 (^GSPC)
70.34%

5-Year Return

HYFT
82.98%
S&P 500 (^GSPC)
61.85%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY27
Revenue 3.83M
Earnings -6.08M
Profit Margin -158.71%

Q2

FY26

Q3

FY26

Q4

FY26

Q1

FY27

-6M
-4M
-2M
0
2M
4M
-140.0%
-120.0%
-100.0%
-80.0%

Analyst Insights

View More

Analyst Price Targets

3.00
4.33 Average
1.0300 Current
5.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/19/2026
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 5 -> 5

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -105.20%

  • Return on Assets (ttm)

    -36.39%

  • Return on Equity (ttm)

    -123.66%

  • Revenue (ttm)

    16.23M

  • Net Income Avi to Common (ttm)

    -17.1M

  • Diluted EPS (ttm)

    -0.2600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.62M

  • Total Debt/Equity (mrq)

    50.41%

  • Levered Free Cash Flow (ttm)

    8.78M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: